Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 919

1.

Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.

Arroyo González R, Kita M, Crayton H, Havrdova E, Margolin DH, Lake SL, Giovannoni G; CARE-MS I and II Investigators..

Mult Scler. 2016 Nov 24. pii: 1352458516677589. [Epub ahead of print]

PMID:
27885061
2.

Lysosomal acid lipase deficiency: Expanding differential diagnosis.

Valayannopoulos V, Mengel E, Brassier A, Grabowski G.

Mol Genet Metab. 2016 Nov 10. pii: S1096-7192(16)30171-8. doi: 10.1016/j.ymgme.2016.11.002. [Epub ahead of print]

PMID:
27876313
3.

Impact of Copayment Changes on Children's Albuterol Inhaler Use and Costs after the Clean Air Act Chlorofluorocarbon Ban.

Galbraith AA, Fung V, Li L, Butler MG, Nordin JD, Hsu J, Smith D, Vollmer WM, Lieu TA, Soumerai SB, Wu AC.

Health Serv Res. 2016 Nov 20. doi: 10.1111/1475-6773.12615. [Epub ahead of print]

PMID:
27868200
4.

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.

Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Ignacio Vargas J, Lee EB.

Ann Rheum Dis. 2016 Nov 17. pii: annrheumdis-2016-210310. doi: 10.1136/annrheumdis-2016-210310. [Epub ahead of print]

5.

The strategic relevance of manufacturing technology: An overall quality concept to promote innovation preventing drug shortage.

Panzitta M, Ponti M, Bruno G, Cois G, D'Arpino A, Minghetti P, Mendicino FR, Perioli L, Ricci M.

Int J Pharm. 2016 Nov 9;516(1-2):144-157. doi: 10.1016/j.ijpharm.2016.11.018. [Epub ahead of print]

PMID:
27838294
6.

Systemic correction of murine glycogen storage disease type IV by an AAV-mediated gene therapy.

Yi H, Zhang Q, Brooks ED, Yang C, Thurberg BL, Kishnani PS, Sun B.

Hum Gene Ther. 2016 Nov 10. [Epub ahead of print]

PMID:
27832700
7.

Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis.

Husson H, Moreno S, Smith LA, Smith MM, Russo RJ, Pitstick R, Sergeev M, Ledbetter SR, Bukanov NO, Lane M, Zhang K, Billot K, Carlson G, Shah J, Meijer L, Beier DR, Ibraghimov-Beskrovnaya O.

Hum Mol Genet. 2016 Jun 1;25(11):2245-2255.

8.

Gaucher disease epidemiology and natural history: a comprehensive review of the literature.

Nalysnyk L, Rotella P, Simeone JC, Hamed A, Weinreb N.

Hematology. 2016 Oct 20:1-9. [Epub ahead of print]

PMID:
27762169
9.

Glucosylsphingosine is a key biomarker of Gaucher disease.

Murugesan V, Chuang WL, Liu J, Lischuk A, Kacena K, Lin H, Pastores GM, Yang R, Keutzer J, Zhang K, Mistry PK.

Am J Hematol. 2016 Nov;91(11):1082-1089. doi: 10.1002/ajh.24491.

PMID:
27441734
10.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators..

Neurology. 2016 Nov 8;87(19):1985-1992.

11.

Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.

Lee EB, Daskalakis N, Xu C, Paccaly A, Miller B, Fleischmann R, Bodrug I, Kivitz A.

Clin Pharmacokinet. 2016 Oct 8. [Epub ahead of print]

PMID:
27722854
12.

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.

Pleat R, Cox TM, Burrow TA, Giraldo P, Goker-Alpan O, Rosenbloom BE, Croal LR, Underhill LH, Gaemers SJ, Peterschmitt MJ.

Mol Genet Metab Rep. 2016 Sep 30;9:25-28.

13.

Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice.

Liou B, Peng Y, Li R, Inskeep V, Zhang W, Quinn B, Dasgupta N, Blackwood R, Setchell KD, Fleming S, Grabowski GA, Marshall J, Sun Y.

Hum Mol Genet. 2016 Sep 20. pii: ddw322. [Epub ahead of print]

PMID:
27655403
14.

Vesivirus 2117: Cell line infectivity range and effectiveness of amplification of a potential adventitious agent in cell culture used for biological production.

Plavsic M, Shick K, Bergmann KF, Mallet L.

Biologicals. 2016 Nov;44(6):540-545. doi: 10.1016/j.biologicals.2016.08.001.

PMID:
27640083
15.

A randomized trial of individual peer support for adults with psychiatric disabilities undergoing civil commitment.

Rogers ES, Maru M, Johnson G, Cohee J, Hinkel J, Hashemi L.

Psychiatr Rehabil J. 2016 Sep;39(3):248-55. doi: 10.1037/prj0000208.

PMID:
27618461
16.

Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.

Strand V, Kosinski M, Chen CI, Joseph G, Rendas-Baum R, Graham NM, van Hoogstraten H, Bayliss M, Fan C, Huizinga T, Genovese MC.

Arthritis Res Ther. 2016 Sep 6;18:198. doi: 10.1186/s13075-016-1096-9.

17.

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon ╬▓-1a in MS.

Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Margolin DH, Thomas DR, Panzara MA, Compston DA; CARE-MS I and CARE-MS II Investigators..

Neurology. 2016 Oct 4;87(14):1464-1472.

18.

Familial hypercholesterolemia/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity.

Foody JM, Vishwanath R.

J Clin Lipidol. 2016 Jul-Aug;10(4):970-86. doi: 10.1016/j.jacl.2016.04.009.

PMID:
27578130
19.

Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia.

Raal FJ, Braamskamp MJ, Selvey SL, Sensinger CH, Kastelein JJ.

J Clin Lipidol. 2016 Jul-Aug;10(4):860-9. doi: 10.1016/j.jacl.2016.02.018.

20.

Collagen IV diseases: A focus on the glomerular basement membrane in Alport syndrome.

Cosgrove D, Liu S.

Matrix Biol. 2016 Aug 27. pii: S0945-053X(16)30071-3. doi: 10.1016/j.matbio.2016.08.005. [Epub ahead of print] Review.

PMID:
27576055
Items per page

Supplemental Content

Loading ...
Support Center